The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism

被引:23
作者
Wells, PS
Rodger, MA
Forgie, MA
Langlois, NJ
Armstrong, L
Carson, NL
Jaffey, J
机构
[1] Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada
[2] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada
[3] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada
[4] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada
[5] Ottawa Hlth Res Inst, Ottawa, ON, Canada
[6] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada
关键词
ACE; angiotensin converting enzyme; venous thromboembolism; deep vein thrombosis; pulmonary embolism;
D O I
10.1160/TH03-03-0170
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The deletion/deletion (D/D) genotype of the angiotensin converting enzyme (ACE) has been purported to be a risk for postoperative thrombosis. This D/D genotype has not been evaluated as a risk factor for idiopathic venous thromboembolism (VTE). The primary objective of the present study was to determine whether the D/D genotype of ACE is independently associated with the occurrence of idiopathic venous thromboembolic disease. We prospectively enrolled consecutive patients with at least one objectively confirmed idiopathic VTE. Friends of cases were recruited as controls and matched to cases by sex, ethnicity, and age. Patients were tested for the ACE I/D polymorphism in addition to factor V Leiden, prothrombin G20210A, and factor VIII levels. Three hundred cases and 300 controls were enrolled; 97% were Caucasian. There were 148 females and 152 males in each group with a mean age of 56.21 years (SD=15.33). The ACE D/D genotype was present in 25.3% of cases and 32.4% of controls for an adjusted odds ratio of 0.66 (95% CI = 0.433 to 0.997). We can conclude that the ACE D/D genotype is protective against idiopathic venous thromboembolism.
引用
收藏
页码:829 / 834
页数:6
相关论文
共 30 条
[1]   Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. [J].
Agnelli, G ;
Prandoni, P ;
Santamaria, MG ;
Bagatella, P ;
Iorio, A ;
Bazzan, M ;
Moia, M ;
Guazzaloca, G ;
Bertoldi, A ;
Tomasi, C ;
Scannapieco, G ;
Ageno, W ;
Ascani, A ;
Villalta, S ;
Frulla, M ;
Mosena, L ;
Girolami, A ;
Vaccarino, A ;
Alatri, A ;
Palareti, G ;
Marchesi, M ;
Ambrosio, GB ;
Parisi, R ;
Doria, S ;
Steidl, L ;
Ambrosini, F ;
Silingardi, M ;
Ghirarduzzi, A ;
Iori, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :165-169
[2]  
[Anonymous], 1998, Modern Epidemiology
[3]   The thrombophilias: Well-defined risk factors with uncertain therapeutic implications [J].
Bauer, KA .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (05) :367-373
[4]   Venous thrombosis - The interaction of genes and environment [J].
Bertina, RM ;
Rosendaal, FR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1840-1841
[5]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[6]  
COUTURAUD F, 2002, SEM VASC MED, V1, P43
[7]  
Dilley A, 1998, AM J EPIDEMIOL, V147, P30
[8]   Genetic determinants of heritable venous thrombosis:: Genotyping methods for factor VLeiden A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation, and algorithms for venous thrombosis investigations [J].
Donnelly, JG ;
Rock, GA .
CLINICAL BIOCHEMISTRY, 1999, 32 (03) :223-228
[9]  
Emmerich J, 2001, THROMB HAEMOSTASIS, V86, P809
[10]  
Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257